Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtDvance: Long-Term Extension Study of GSK1070806 in Atopic Dermatitis
NCT06447506Phase 2Terminated
- Sponsor
- GSK
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised trial of aletekitug in atopic dermatitis (AD) (9 arms), sponsored by GSK. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With TEAEs Leading to Permanent Discontinuation and 2 more. Started Jun 2024; status: terminated.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06447506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447506.